(function(){
			var content_array=["<p><b><span>关于<\/span><\/b><b><span>BIO International Convention<\/span><\/b><\/p> \n<p><span>美国生物技术大会暨展览会<\/span><span>(BIO International Convention)<\/span><span>始创于<\/span><span>1993<\/span><span>年，致力于生物技术和医药产业的发展及国际间的交流合作，促进生物产业的全面进步。目前，该展会已经发展成为全球规模最大、规格最高的生物技术盛会，在业界享有极高的声誉。<span id=\"spanHghlteb11\">今年将<\/span>有来自<\/span><span>76<\/span><span>国家的超过<\/span><span>16,000<\/span><span>名生物技术、生物医药领域的专业人士及嘉宾参加。<\/span><\/p> \n<p><b><span>关于科济生物<\/span><\/b><\/p> \n<p><span>科济生物是中国首家专注于嵌合抗原受体修饰的<\/span><span>T<\/span><span>细胞<\/span><span> (CAR-T)<\/span><span>免疫治疗的创新型企业。科济生物开展了全球首个针对肝细胞癌的<\/span><span> CAR-GPC3<\/span><span>临床试验、针对胶母细胞瘤<\/span><span>(GBM)<\/span><span>的<\/span><span>EGFR\/EGFRvIII<\/span><span>双靶点的<\/span><span>CAR-T <\/span><span>的临床试验，针对胃癌、胰腺癌的<\/span><span>Claudin18.2<\/span><span>靶点治疗的<\/span><span>CAR-T <\/span><span>的临床试验，以及应用人源化<\/span><span>CD19 CAR-T<\/span><span>治疗白血病及淋巴瘤临床研究。<\/span><\/p> \n<p><span>更多新闻，请访问科济生物网站<\/span><span><a href=\"https:\/\/t.prnasia.com\/t\/ImVKRVQ0\" target=\"_blank\" rel=\"nofollow\">www.carsgen.com<\/a><\/span><\/p>"];
			$("#dvExtra").html(content_array[0]);})();